U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C24H31NO6
Molecular Weight 429.506
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SARPOGRELATE

SMILES

COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1

InChI

InChIKey=FFYNAVGJSYHHFO-UHFFFAOYSA-N
InChI=1S/C24H31NO6/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27)

HIDE SMILES / InChI

Molecular Formula C24H31NO6
Molecular Weight 429.506
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/sarpogrelate.html | https://www.ncbi.nlm.nih.gov/pubmed/10980267 | https://clinicaltrials.gov/ct2/show/NCT01165567 | http://www.e-search.ne.jp/~jpr/PDF/MT02.PDF

Sarpogrelate (brand name Anplag; former developmental code names MCI-9042, LS-187,118) is a drug which acts as an antagonist at the 5HT2A and 5-HT2B receptors. It blocks serotonin-induced platelet aggregation and has applications in the treatment of many diseases including diabetes mellitus, Buerger's disease, Raynaud's disease, coronary artery disease, angina pectoris, and atherosclerosis.

CNS Activity

Curator's Comment: According to information supplied by the manufacturers, the brain tissue concentration of sarpogrelate was 0.25–0.5% of the plasma concentration, in a w14 tracer experiment using Cx-labeled sarpogrelate

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.38 nM [Ki]
6.11 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Anplag

Approved Use

INDICATIONS. Improvement of ischemic symptoms including ulcer, pain and feeling of coldness, associated with chronic arterial occlusion
Preventing
Anplag

Approved Use

INDICATIONS. Improvement of ischemic symptoms including ulcer, pain and feeling of coldness, associated with chronic arterial occlusion
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.3636 μg/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.7218 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
565 μg/mL
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
506.5 μg/mL
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
62.4 μg/mL
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
49.3 μg/mL
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
721.4 μg/L
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
467.3 μg/L
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
761 μg/L
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.2908 μg × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.5958 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1754 μg × h/mL
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1358.4 μg × h/mL
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
361 μg × h/mL
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
291.1 μg × h/mL
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2352.5 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1927.3 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
1772.7 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.753 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.753 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.59 h
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.12 h
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.44 h
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.66 h
100 mg 2 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.23 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.45 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
0.7 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SARPOGRELATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
SARPOGRELATE serum
Homo sapiens
96.8%
SARPOGRELATE plasma
Homo sapiens
72%
1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
200 mg 3 times / day multiple, oral
Higher than recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Other AEs: Elevated liver enzymes, Upper gastrointestinal symptoms...
Other AEs:
Elevated liver enzymes (3.3%)
Upper gastrointestinal symptoms (0.8%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Upper gastrointestinal symptoms 0.8%
200 mg 3 times / day multiple, oral
Higher than recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Elevated liver enzymes 3.3%
200 mg 3 times / day multiple, oral
Higher than recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [Inhibition 10 uM]
no [Inhibition 10 uM]
no [Inhibition 10 uM]
no [Inhibition 10 uM]
no
yes [IC50 0.195 uM]
yes (co-administration study)
Comment: Co-administration increased Metoprolol AUCt by 1.53-fold and Cmax by 1.62-fold
Page: 1.0
yes [IC50 0.201 uM]
yes [IC50 19.4971 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Serotonin potentiates angiotensin II--induced vascular smooth muscle cell proliferation.
2001 Dec
Antithrombotic activity of AT-1015, a potent 5-HT(2A) receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time.
2001 Dec 21
Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans.
2001 Jul
Monocyte chemotactic protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation.
2001 Jul-Aug
Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency.
2001 Jun
Assessment of affinity and dissociation ability of a newly synthesized 5-HT2 antagonist, AT-1015: comparison with other 5-HT2 antagonists.
2001 Nov
Binding affinity of a newly synthesized 5-HT2 antagonist, AT-1015 (N-[2-[4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-piperidino]ethyl]-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate), in the rabbit platelet membrane.
2001 Oct
Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart.
2001 Sep
[Involvement of peripheral 5-HT2A receptor activation in inflammatory pain].
2001 Sep
AT-1015, a newly synthesized 5-HT2 receptor antagonist, dissociates slowly from the 5-HT2 receptor sites in rabbit cerebral cortex membrane.
2002 Aug
Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris.
2002 Aug
Effects of chronic administration of sarpogrelate on systolic blood pressure of spontaneously hypertensive rats: comparison with quinapril.
2002 Feb
Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries.
2002 Feb 1
DOI, a 5-HT2 receptor agonist, induces renal vasodilation via nitric oxide in anesthetized dogs.
2002 Feb 15
Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats.
2002 Jan
[Pharmacological analysis of inhibitory effect of sarpogrelate hydrochloride on human radial artery contraction].
2002 Jan
Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease.
2002 Jan
Changed responsiveness of the detrusor in rabbits with alloxan induced hyperglycemia: possible role of 5-hydroxytryptamine for diabetic bladder dysfunction.
2002 Jul
Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes.
2002 May
Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats.
2003 Dec 1
Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism.
2003 May
The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation.
2003 May
Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling.
2003 May 30
Effects of R-102444, an orally active 5-HT2A receptor antagonist, in rat models of peripheral vascular disease.
2004 Feb
Sarpogrelate: cardiovascular and renal clinical potential.
2004 Jul
New treatment of lumbar disc herniation involving 5-hydroxytryptamine2A receptor inhibitor: a randomized controlled trial.
2005 Apr
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.
2005 Sep
Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study.
2006 May
Livedo racemosa as a cutaneous manifestation of polycythemia vera.
2006 May-Jun
Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease.
2006 Nov
5-HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury.
2006 Sep 27
Sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, attenuates neurogenic pain induced by nucleus pulposus in rats.
2007 Feb 1
Identification of a key amino acid of the human 5-HT(2B) serotonin receptor important for sarpogrelate binding.
2007 Jul
Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.
2008 Apr
Both 5-hydroxytryptamine 5-HT2A and 5-HT1B receptors are involved in the vasoconstrictor response to 5-HT in the human isolated internal thoracic artery.
2008 Jul
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.
2008 Mar
Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS.
2009 Aug
Chronic treatment of hydroxytryptamine type 2a receptor antagonist sarpogrelate hydrochloride modulates the vasoreactivity of serotonin in experimental rabbit vein grafts.
2009 Sep
Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine(2A) antagonist, augments autologous bone marrow mononuclear cell implantation-induced improvement in endothelium-dependent vasodilation in patients with critical limb ischemia.
2010 Jan
Patents

Patents

Sample Use Guides

The usual dosage for adult patients is 100 mg of sarpogrelate hydrochloride, administered after meal three times a day. The dosage may be adjusted according to the patient’s age and symptoms.
Route of Administration: Oral
Stably expressing cell lines were constructed in HEK293 cells by transfecting with Lipofectamine 2000 reagent and selecting with 0.5 mg/ml G418-containing growth medium. Cells were split into 24-well plates at a density of 105 cells /well and labeled with 3 μCi/ml [3H]myo-inositol in serum-free DMEM for 24 h. Then the cells were washed with the assay medium (20 mM LiCl, 130 mM NaCl, 900 μM NaH2PO4, 5.4 mM KCl, 1.8 mM CaCl2, and 25 mM glucose in 20 mM HEPES, pH 7.4) and incubated with both SARPOGRELATE (10−9 – 10−4 M) at 37°C for 1 h. Cell extracts, in 10 mM formic acid, were applied to a 1-ml AG1-X8 resin (100 – 200 mesh; Assist Co., Tokyo) column before elution by buffer containing 1 M ammonium formate and 0.1 M formic acid. Radioactivity was measured by a liquid scintillation spectrophotometer.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:16:38 GMT 2025
Edited
by admin
on Mon Mar 31 18:16:38 GMT 2025
Record UNII
19P708E787
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
4-(1-(2-(3-METHOXYPHENETHYL)PHENOXY)-3-(DIMETHYLAMINO)PROPAN-2-YLOXY)-4-OXOBUTANOIC ACID SARPOGRELATE
Preferred Name English
SARPOGRELATE
INN   WHO-DD  
INN  
Official Name English
Sarpogrelate [WHO-DD]
Common Name English
BUTANEDIOIC ACID, 1-(2-(DIMETHYLAMINO)-1-((2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)METHYL)ETHYL) ESTER
Systematic Name English
BUTANEDIOIC ACID, MONO(2-(DIMETHYLAMINO)-1-((2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)METHYL)ETHYL) ESTER
Common Name English
sarpogrelate [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1327
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
NCI_THESAURUS C66885
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID7048328
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
PRIMARY
INN
6611
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
PRIMARY
CAS
135309-80-7
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
SUPERSEDED
PUBCHEM
5160
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
PRIMARY
EVMPD
SUB10455MIG
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
PRIMARY
FDA UNII
19P708E787
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
PRIMARY
DRUG CENTRAL
2423
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
PRIMARY
MESH
C064294
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
PRIMARY
DRUG BANK
DB12163
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
PRIMARY
NCI_THESAURUS
C73158
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
PRIMARY
ChEMBL
CHEMBL52939
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
PRIMARY
SMS_ID
100000084098
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
PRIMARY
IUPHAR
210
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
PRIMARY
CAS
125926-17-2
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
PRIMARY
WIKIPEDIA
SARPOGRELATE
Created by admin on Mon Mar 31 18:16:38 GMT 2025 , Edited by admin on Mon Mar 31 18:16:38 GMT 2025
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
ACTIVE MOIETY